{"nctId":"NCT01167010","briefTitle":"A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma","startDateStruct":{"date":"2011-04"},"conditions":["Asthma"],"count":552,"armGroups":[{"label":"Formoterol/Budesonide","type":"EXPERIMENTAL","interventionNames":["Drug: Formoterol/Budesonide"]},{"label":"Foraseq","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Foraseq"]},{"label":"Alenia","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Alenia"]}],"interventions":[{"name":"Formoterol/Budesonide","otherNames":[]},{"name":"Foraseq","otherNames":["Formoterol/Budesonide"]},{"name":"Alenia","otherNames":["Formoterol/Budesonide"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Sign the ICF;\n* ≥ 12 years old;\n* Have a diagnosis of mild to moderate persistent asthma diagnosis, as per the GINA classification (www.ginasthma.com),18 with symptoms for at least 6 months and clinically stable for at least 1 month with the ACQ-7 test \\<3,0;\n* Current use of inhaled corticosteroid (equivalent to 1000 µg of beclomethasone dipropionate) whether associated or not with long-term β2 adrenergics and relief medication (salbutamol or equivalent);\n* Initial FEV1 of at least 50% of the normal value expected;\n* Serum cortisol evaluation within the normal limits\n\nExclusion Criteria:\n\n* Use of oral or parenteral corticosteroid within the last 3 months before the study;\n* Hospitalization needed due to asthma within the last 3 months before the study;\n* Active smokers, defined as the consumption of cigarettes, pipes, cigars, or any other form of smoking in any amount within the last 3 months;\n* Presence of serious co-morbidities, such as cardiovascular, renal, liver, neurological, neoplastic, hematological, infectious, dermatologic, neurological, or psychiatric disease, or chronic respiratory disease other than asthma;\n* Recent participation (\\<6 months) or expected participation in other clinical trials involving drug products of any nature or in studies consisting of any form of intervention for the treatment of asthma;\n* Intolerance or allergy to any component of the drugs evaluated in the study;\n* Pregnant or lactating women;\n* Chronic use of routine β-blockers orally or intravenously, including ophthalmic solutions.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Forced Expiratory Volume in 1 Second (FEV1) at the Final Visit (FV)","description":"The primary efficacy analysis was performed by evaluating non-inferiority of Eurofarma's device compared to Alenia® in relation to FEV1 (in liters) in FV in the PP population","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.53","spread":"0.79"},{"groupId":"OG001","value":"2.51","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"FEV1 (L) in VF in the ITT Population, to Assess the Difference Between the Three Groups","description":"The mean FEV1 (L) in VF were compared between the three groups using the nonparametric Kruskal-Walllis test and the ITT population. A nonparametric test was used since the variable did not show normal distribution in the Foraseq® group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":"0.77"},{"groupId":"OG001","value":"2.52","spread":"0.80"},{"groupId":"OG002","value":"2.46","spread":"0.88"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":154},"commonTop":["Left and posterior knee trauma infection"]}}}